These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 26686752)

  • 21. In silico assessment of adverse drug reactions and associated mechanisms.
    Ivanov SM; Lagunin AA; Poroikov VV
    Drug Discov Today; 2016 Jan; 21(1):58-71. PubMed ID: 26272036
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.
    Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D
    Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity testing: creating a revolution based on new technologies.
    Bhogal N; Grindon C; Combes R; Balls M
    Trends Biotechnol; 2005 Jun; 23(6):299-307. PubMed ID: 15922082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In silico methods for toxicity prediction.
    Combes RD
    Adv Exp Med Biol; 2012; 745():96-116. PubMed ID: 22437815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. QSAR, Read-across and REACH.
    Barratt MD
    Altern Lab Anim; 2003 Nov; 31(5):463-5. PubMed ID: 15598173
    [No Abstract]   [Full Text] [Related]  

  • 26. Toxicology is IN: in silico, in vitro, integrated testing strategy.
    Caloni F; Benfenati E; Sambuy Y
    ALTEX; 2016; 33(2):187-8. PubMed ID: 27032091
    [No Abstract]   [Full Text] [Related]  

  • 27. Proposing a scientific confidence framework to help support the application of adverse outcome pathways for regulatory purposes.
    Patlewicz G; Simon TW; Rowlands JC; Budinsky RA; Becker RA
    Regul Toxicol Pharmacol; 2015 Apr; 71(3):463-77. PubMed ID: 25707856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The in chemico-in silico interface: challenges for integrating experimental and computational chemistry to identify toxicity.
    Cronin MT; Bajot F; Enoch SJ; Madden JC; Roberts DW; Schwöbel J
    Altern Lab Anim; 2009 Nov; 37(5):513-21. PubMed ID: 20017580
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternatives to animal testing in toxicity testing: Current status and future perspectives in food safety assessments.
    Reddy N; Lynch B; Gujral J; Karnik K
    Food Chem Toxicol; 2023 Sep; 179():113944. PubMed ID: 37453475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Towards an integrated in vitro strategy for repeated dose toxicity testing.
    Vanhaecke T; Pauwels M; Vinken M; Ceelen L; Rogiers V
    Arch Toxicol; 2011 May; 85(5):365-6. PubMed ID: 21512801
    [No Abstract]   [Full Text] [Related]  

  • 31. Contribution of new technologies to characterization and prediction of adverse effects.
    Rouquié D; Heneweer M; Botham J; Ketelslegers H; Markell L; Pfister T; Steiling W; Strauss V; Hennes C
    Crit Rev Toxicol; 2015 Feb; 45(2):172-83. PubMed ID: 25615431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian integrated testing strategy to assess skin sensitization potency: from theory to practice.
    Jaworska J; Dancik Y; Kern P; Gerberick F; Natsch A
    J Appl Toxicol; 2013 Nov; 33(11):1353-64. PubMed ID: 23670904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometry imaging in drug development.
    Nilsson A; Goodwin RJ; Shariatgorji M; Vallianatou T; Webborn PJ; Andrén PE
    Anal Chem; 2015 Feb; 87(3):1437-55. PubMed ID: 25526173
    [No Abstract]   [Full Text] [Related]  

  • 34. Computational approaches for skin sensitization prediction.
    Wilm A; Kühnl J; Kirchmair J
    Crit Rev Toxicol; 2018 Oct; 48(9):738-760. PubMed ID: 30488745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods.
    Tsaioun K; Blaauboer BJ; Hartung T
    ALTEX; 2016; 33(4):343-358. PubMed ID: 27806179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Building on a solid foundation: SAR and QSAR as a fundamental strategy to reduce animal testing.
    Sullivan KM; Manuppello JR; Willett CE
    SAR QSAR Environ Res; 2014; 25(5):357-65. PubMed ID: 24773450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Troubleshooting computational methods in drug discovery.
    Kortagere S; Ekins S
    J Pharmacol Toxicol Methods; 2010; 61(2):67-75. PubMed ID: 20176118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toxicity testing: the need for new maps for the future.
    Balls M
    Altern Lab Anim; 2011 Oct; 39(5):417-8. PubMed ID: 22103936
    [No Abstract]   [Full Text] [Related]  

  • 40. Predicting the future: opportunities and challenges for the chemical industry to apply 21st-century toxicity testing.
    Settivari RS; Ball N; Murphy L; Rasoulpour R; Boverhof DR; Carney EW
    J Am Assoc Lab Anim Sci; 2015 Mar; 54(2):214-23. PubMed ID: 25836969
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.